On September 25, 2023 The board of directors (the "Board") of Hansoh Pharmaceutical Group Company Limited
(the "Company" and together with its subsidiaries, the "Group") reported that "HS-20105", a Category 1 therapeutic biological product self-developed by Shanghai Hansoh Biomedical Technology Company Limited* (上海翰森生物醫藥科技有限公司) and Changzhou Hansoh Pharmaceutical Company Limited* (常州恒邦藥業有限公司), both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People’s Republic of China, and is intended to be used for the treatment of advanced solid tumors (Press release, Jiangsu Hansoh Pharmaceutical, SEP 25, 2023, View Source [SID1234654211]). The specific indication will be determined after the completion of clinical research.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ABOUT "HS-20105"
HS-20105 is an antibody-drug conjugate formed by coupling humanized anti-Trop-2 monoclonal antibody of IgG1 subtype with cytotoxic payload (DNA topoisomerase I inhibitor) by the cleavable linker.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady